ABSTRACT
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Owing to the incorporation of risk-adapted therapy and the arrival of new directed agents, the cure rate and survival of patients with ALL have improved dramatically, get near to 90%. In Latin American countries, the mortality rates of ALL are high, for example in Colombia, during the last decade, ALL has been the most prevalent cancer among children between 0-14 years of age. In the face of this public health problem and coupled with the fact that the knowledge of the proteome of the child population is little, our investigation proposes the study of the plasma proteome of Colombian children diagnosed with B-cell ALL (B-ALL) to determine potential disease markers that could reflect processes altered by the presence of the disease or in response to it. A proteomic study by LC-MS/MS and quantification by label-free methods were performed in search of proteins differentially expressed between healthy children and those diagnosed with B-ALL. We quantified a total of 472 proteins in depleted blood plasma, and 25 of these proteins were differentially expressed (fold change >2, Bonferroni-adjusted P-values <0.05). Plasma Aggrecan core protein, alpha-2-HS-glycoprotein, coagulation factor XIII A chain and gelsolin protein were examined by ELISA assay and compared to shotgun proteomics results. Our data provide new information on the plasma proteome of Colombian children. Additionally, these proteins may also have certain potential as illness markers or as therapeutic targets in subsequent investigations.
Subject(s)
Blood Proteins/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood , Proteomics , Case-Control Studies , Child , Child, Preschool , Colombia , Female , Gene Ontology , Humans , Male , Protein Interaction MapsABSTRACT
Resumen En Colombia, durante la última década, la leucemia linfoblástica aguda (LLA) ha causado más del 40% de las muertes por cáncer en menores de edad. Entre los factores que influyen en estas cifras, el diagnóstico tardío es uno de los factores que más afecta el éxito del tratamiento. Por lo anterior, esta investigación se centró en el estudio del proteoma plasmático de niños colombianos diagnosticados con LLA tipo B, en comparación con controles en la búsqueda de proteínas que podrían ser clasificadas como biomarcadores de diagnóstico. En vista de los avances en las herramientas proteómicas y de espectrometría de masas y teniendo en cuenta que son una alternativa para abordar la complejidad molecular de enfermedades como el cáncer, se utilizó una aproximación proteómica basada en una separación por electroforesis bidimensional diferencial (2DE-DIGE) con posterior separación por cromatografía líquida acoplada a espectrometría de masas (LC-MS) en tándem. Se encontraron ocho proteínas con expresión diferencial en plasma de pacientes con LLA-B, entre las cuales resaltan la Serotransferrina, la Alfa-1-antitripsina, la Haptoglobina, la Alfa-2-glicoproteína de zinc y el Complemento C3.
Abstract In Colombia, during the last decade, acute lymphoblastic leukemia (ALL) has caused more than 40% of cancer deaths in children. Among the factors that influence these figures, late diagnosis is one of the factors that affects the treatment success. Therefore, this research focused on the plasma proteome study of Colombian children diagnosed with B-cell ALL, as compared with healthy controls in the search of proteins that could be classified as diagnostic biomarkers. Now, in view of the advances in the proteomics and mass spectrometry tools and taking into account that they are an alternative to address the molecular complexity of diseases such as cancer, a proteomic approach, based on bidimensional difference gel electrophoretic separation (2DE-DIGE) coupled to LC-MS/ MS, was used. We found eight differentially expressed proteins in plasma from B-cell ALL patients as follows: Serotransferrin, Alpha-1-antitrypsin, Haptoglobin, Zinc-alpha-2-glycoprotein, and Complement C3.
Resumo Na Colômbia, durante a última década, a leucemia linfoblastica aguda (LLA) tem sido o câncer com maior incidência, com mais de 40% das mortes por câncer em menores atribuídas a essa doença. Entre os fatores que influenciam esses números, o diagnóstico tardio talvez seja o fator mais sensível que afeta negativamente o sucesso do tratamento. Esta pesquisa enfocou o estudo do proteoma plasmático de crianças colombianas diagnosticadas com LLA tipo B, dada a sua alta incidência, em comparação com controles na busca por proteínas que poderiam ter potencialidade para serem classificadas como biomarcadores diagnósticos. Agora, em vista dos avanços nas ferramentas de proteômica e espectrometria de massa e sabendo que eles são uma alternativa para abordar a complexidade molecular de doenças como o câncer, usamos uma abordagem proteômica baseada em uma separação por eletroforese bidimensional diferencial (2DE-DIGE) com subsequente separação por cromatografia líquida acoplada a espectrometria de massa em tandem. Encontramos 8 proteínas com expressão diferencial no plasma de pacientes com LBA, dentre os quais a Serotransferrina, a Alfa-1-antitripsina, a Haptoglobina, a Glicoproteína alfa-2-zinco e o Complemento C3.
